Government ❯ Regulatory Affairs

FDA

Drug Warnings Clinical Trial Regulations Drug Approval Process

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

The rare-disease specialist moves to add a Phase 3 hepatitis D antibody ahead of a 2026 efficacy readout.

FDA Issues New Warning on Unapproved Tianeptine 'Gas Station Heroin' Products